Alere Inc (ALR) 43.40 $ALR
Alere (ALR) Disappoints; Misses on Earnings, Revenues in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:44AM CST
Alere Inc. (ALR) reported disappointing fourth-quarter 2014 results with both its top and bottom line missing the Zacks Consensus Estimate.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ALR: 43.40 (-0.40), SURG: 4.44 (-0.02)
Alere's (ALR) CEO Namal Nawana on Q4 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:07PM CST
ALR: 43.40 (-0.40)
Alere misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:02AM CST
ALR: 43.40 (-0.40)
Alere Inc. Announces Fourth Quarter 2014 Results
PR Newswire - Tue Feb 10, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, announced its financial results for the quarter ended December 31, 2014.
ALR: 43.40 (-0.40)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:30PM CST
WYN: 90.57 (+0.93), TLM: 7.63 (-0.03), CYNO: 31.37 (+0.80), PCG: 54.06 (-1.14), KKR: 24.42 (+0.06), GWR: 94.92 (-0.19), CDW: 37.03 (+0.63), ALLT: 9.15 (+0.02), HOT: 78.55 (+0.67), SAVE: 79.32 (-0.80), NSP: 48.91 (+1.20), MWW: 6.00 (+0.11), ACM: 27.79 (+0.82), DF: 16.19 (-0.11), REGN: 402.40 (+0.66), KO: 41.99 (-0.18), MLM: 145.23 (+3.15), RAI: 71.86 (-1.23), HCP: 42.87 (+0.20), SEE: 46.05 (-0.16), ENTG: 13.50 (-0.15), TAP: 72.82 (-0.96), ALR: 43.40 (-0.40), HNT: 55.97 (-0.43), OMC: 77.56 (+1.09), IMN: 3.93 (+0.13), SALE: 16.41 (+0.13), NILE: 29.02 (+0.07), CVS: 102.63 (-0.37), SFUN: 6.74 (-0.01)
Will Alere (ALR) Surprise Earnings Estimates This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 9:04AM CST
Alere Inc. (ALR) is set to report fourth-quarter 2014 results on Feb 10.
ACT: 285.37 (+3.71), ALNY: 95.54 (+1.67), UNH: 109.44 (-0.40), ALR: 43.40 (-0.40)
Alere Schedules Fourth Quarter 2014 Earnings Conference Call
PR Newswire - Tue Feb 03, 4:55PM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that it will release its financial results for the fourth quarter, ended December 31, 2014. The Company will host a conference call beginning at 8:30 a.m. ET on Tuesday, February 10, 2015, to discuss these results and provide business updates.
ALR: 43.40 (-0.40)
Chembio Acquires Rights to SURE CHECK(R) HIV 1/2 Assay Effective June 1, 2016
GlobeNewswire - Thu Jan 22, 9:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has entered into an agreement with StatSure Diagnostic Systems, Inc. (SDS) to acquire SDS' interest in the SURE CHECK HIV 1/2 Assay, effective June 1, 2016.
ALR: 43.40 (-0.40), CEMI: 3.96 (-0.04)
Chembio to own full rights to HIV 1/2 test by mid-2016
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:59AM CST
ALR: 43.40 (-0.40), CEMI: 3.96 (-0.04)
Health Care Supplies Stocks Technical Review - Cerus, Unilife, DENTSPLY Intl., Alere, and Align Technology
PR Newswire - Thu Jan 22, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Cerus Corporation (NASDAQ: CERS), Unilife Corporation (NASDAQ: UNIS), DENTSPLY International Inc. (NASDAQ: XRAY), Alere Inc. (NYSE: ALR), and Align Technology Inc. (NASDAQ: ALGN). Free research report on Cerus can be accessed at http://get.Investor-Edge.com/pdf/?c=Cerus&...amp;s=CERS. On Wednesday, January 21, 2015, the NASDAQ Composite ended at 4,667.42, up 0.27%, the Dow Jones Industrial Average advanced 0.22%, to finish the day at 17,554.28, and the S&P 500 closed at 2,032.12, up 0.47%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.90, up 0.11%, with the index also advancing 10.82% in the previous three months. Register for your complimentary reports at the links given below.
CERS: 5.53 (+0.08), ALGN: 56.90 (-0.34), UNIS: 4.32 (+0.06), ALR: 43.40 (-0.40), XRAY: 52.74 (+0.32)
Global Breath Analyzers Market 2014-2019 - Technology, by Application, by End User Analysis of the $1.53 Billion Industry
M2 - Mon Jan 19, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/9nfpk8/breath_analyzers) has announced the addition of the "Breath Analyzers Market by Technology, by Application, by End User - Analysis & Global Forecast to 2019" report to their offering. This market is expected to reach $1.53 billion in 2019 from $479.3 million in 2014 at a CAGR of 26.3% The breath analyzers market is categorized into four broad segments, namely, technology, applications, end users, and regions. The market, by technology, comprises fuel cell technology, semiconductor oxide sensor technology, and others. In 2014, the fuel cell technology segment accounted for the major share of the global market, by technology. Alcohol detection accounted for the largest share of the global market by application. Increasing alcohol and drug abuse, stringent government laws and regulations, an increase in the number of approvals from regulatory bodies, growing prominence of smartphone-based breath analyzers, and innovative product offerings (especially for medical applications) have stimulated the adoption of breath analyzers in the industry. However, in spite of numerous benefits, certain challenges such as inaccuracy and hygiene concerns are restraining the growth of this market. On the basis of end users, the breath analyzers market is segmented by law enforcement agencies, enterprises and individuals. Law enforcement agencies accounted for the largest share of the global market. Based on region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Africa, and Latin America) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Dynamics 6 Industry Trends 7 Breath Analyzers Market, By Technology 8 Breath Analyzers Market, By Application 9 Breath Analyzers Market, By End User 10 Breath Analyzers Market, By Geography 11 Competitive Landscape 12 Company Profiles - AK GlobalTech Corporation - Akers Biosciences, Inc. - Alcohol Countermeasure Systems Corporation - Alere, Inc. - BACtrack, Inc. - Dr?gerwerk AG & Co. KGaA - EnviteC-Wismar GmbH (A Honeywell Company) - Intoximeters, Inc. - Lifeloc Technologies - Mpd, Inc. - Quest Products, Inc. For more information visit http://www.researchandmarkets.com/research/9n..._analyzers
ALR: 43.40 (-0.40)
Global Infectious Disease Diagnostics Market 2014-2019 - Product, Application, Technology & End User Analysis of the $18 Billion Industry
M2 - Mon Jan 19, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vljzx/infectious) has announced the addition of the "Infectious Disease Diagnostics Market by Product, Application, Technology, End User - Global Forecast to 2019" report to their offering. The infectious disease diagnostics market is expected to grow at CAGR of 7.9% to reach $18.15 billion by 2019 from $12.42 billion in 2014 Increasing Prevalence of Deadly Infectious Disease and Need For Highly Specific and Sensitive Technologies for Rapid Diagnosis to Drive Growth of the IDD Market The immunodiagnostics and polymerase chain reaction technology segments accounted for the lion's share of the global IDD market by technology, owing to growing need for advanced technologies for rapid diagnosis of infectious diseases. On the basis of application, the IDD market is categorized into the Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), human papillomavirus (HPV), methicillin-resistant Staphylococcus aureus (MRSA), and others (Influenza, Ebola, Typhoid, Malaria, and Dengue, among others). Hospital-acquired MRSA infections, human papillomavirus, and AIDS are expected to be new revenue pockets in the applications market. The rising prevalence of these diseases globally is the major factor driving the growth of the aforementioned markets. On the basis of product, the IDD market is segmented into instruments, consumables (reagents and assays), and software & services. Among products, consumables are estimated to be the fastest-growing market owing to its growing adoption in emerging infectious disease diagnostics worldwide. On the basis of end user, the market is segmented into hospital laboratories, reference labs, physician's office labs, academics, and others (blood banks, local public health laboratories, home health agencies, nursing homes, point of care, self-testing). Hospital laboratories are expected to be the fastest-growing market in the forecast period. Owing to the complexity and highly specialized nature of diagnostic tests for infectious diseases, hospital laboratories are expected to grow at the fastest rate in the forecast period, from 2014 to 2019. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Infectious Disease Diagnostics Market, By Product 8 Infectious Disease Diagnostics Market, By Application 9 Infectious Disease Diagnostics Market, By Technique 10 Infectious Disease Diagnostics Market, By End User 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - Abbott Laboratories - Alere, Inc. - Becton, Dickinson & Co. - Bio-Rad Laboratories - Biom?rieux - Danaher Corporation - Johnson and Johnson - Roche Diagnostics - Siemens Healthcare - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8vljzx/infectious
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), BDX: 143.71 (+0.72), DHR: 86.81 (+0.21), ALR: 43.40 (-0.40)
Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019
M2 - Fri Jan 16, 8:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/cl7fxt/microbiology) has announced the addition of the "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019" report to their offering. The global clinical microbiology market is expected to reach $12,411.36 million in 2019 at a CAGR of 13.03% between 2014 and 2019. Clinical microbiology consists of a wide array of techniques for the detection of infectious diseases. The respiratory diseases segment accounted for the largest application segment of the clinical microbiology market in 2014. According to the WHO, in 2012, there were about 450,000 new cases of multidrug-resistant tuberculosis (MDR-TB), and extensively drug-resistant tuberculosis (XDR-TB) was identified in 92 countries. Furthermore, the outbreak of new diseases such as Ebola is expected to increase the disease burden and the demand for clinical microbiology products. The microbiology market is segmented on the basis of applications into clinical, energy, environment, food, manufacturing, and pharmaceuticals. The food application segment is expected to grow at the highest CAGR between 2014 and 2019 however, the pharmaceuticals application segment accounted for the largest share of the microbiology market in 2014. On the basis of products, the clinical microbiology market is segmented into consumables and instruments. The clinical microbiology consumables market is further bifurcated into kits and reagents, whereas the instruments market is sub segmented into automated microbiology instruments, laboratory instruments, and microbiology analyzers. The microbiology analyzers are further categorized into mass spectrometers, microscopes, and molecular diagnostics instruments. The laboratory instruments are further categorized into anaerobic gas systems, automated gram strainers, automated petri dish fillers, autoclave sterilizers, bacterial colony counters, incubators, microbial air samplers, and other laboratory instruments. Clinical microbiology finds applications in a large number of disease diagnosis. The clinical microbiology market on the basis of applications are segmented into bloodstream infections, gastrointestinal diseases, periodontal diseases, respiratory diseases, sexually transmitted diseases, urinary tract infections, and other diseases. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Microbiology Market, By Applications 8 Clinical Microbiology Market, By Product 9 Clinical Microbiology Market, By Applications 10 Clinical Microbiology Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - Biom?rieux SA - Bruker Corporation - Cepheid - Danaher Corporation - F. Hoffmann-LA Roche Ltd. - Hologic, Inc. - Siemens AG For more information visit http://www.researchandmarkets.com/research/cl...crobiology
ABT: 46.09 (+0.87), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), ALR: 43.40 (-0.40), HOLX: 30.46 (+0.21)
Alere (ALR) Closes Alere Health Sale to Optum for $600M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 12:30PM CST
The sale of Alere Health is part of Alere Inc.'s (ALR) key strategic objective to divest its non-core operations to focus on core areas like rapid diagnostics and improve balance sheet strength.
ABT: 46.09 (+0.87), BDX: 143.71 (+0.72), UNH: 109.44 (-0.40), ALR: 43.40 (-0.40)
Alere Set to Possibly Pullback After Yesterday's Rally of 1.31%
Comtex SmarTrend(R) - Fri Jan 09, 4:34PM CST
Alere (AMEX:ALR) traded in a range yesterday that spanned from a low of $39.58 to a high of $40.68. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALR: 43.40 (-0.40)
Alere Inc. Completes Divestiture of Alere Health
PR Newswire - Fri Jan 09, 3:10PM CST
Alere Inc. (NYSE: ALR) today announced the completion of the previously announced sale of Alere Health and its subsidiaries, which provide leading condition management, case management, wellbeing, wellness and women's and children's health services to regional and local health plans, Fortune 500 employers and state governments, to Optum for $600 million in cash.
ALR: 43.40 (-0.40)
Alere's (ALR) Influenza Test Gets CLIA Waiver from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 11:10AM CST
With the CLIA waiver from the FDA, Alere Inc.'s (ALR) i Influenza A & B test can now be used across a wide variety of clinical settings.
ABT: 46.09 (+0.87), JNJ: 99.62 (+1.18), BDX: 143.71 (+0.72), ALR: 43.40 (-0.40)
Alere Receives FDA CLIA Waiver for Alere(TM) i Influenza A & B Test
PR Newswire - Wed Jan 07, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere(TM) i Influenza A & B test, the only molecular test to detect and differentiate influenza A and B virus in under 15 minutes. Alere i Influenza A & B is the first-ever molecular test to receive a CLIA (Clinical Laboratory Improvement Amendments) waiver, which allows for broad use by healthcare providers, ranging from hospitals and physician offices to clinics and other healthcare settings.
ALR: 43.40 (-0.40)
Alere to Present at 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 05, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that CEO and President Namal Nawana will present at the 33rd annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 7:30 a.m. PST. The conference will be held at the Westin St. Francis in San Francisco, Calif.
JPM: 59.67 (+0.10), ALR: 43.40 (-0.40)
Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021
M2 - Mon Dec 15, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/267psb/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.) to reach $19.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alere Inc - Bio Rad Laboratories Inc - Cepheid - Hologic GenProbe Inc - Hologic Inc - Illumina Inc - Immucor Inc - Life Technologies Corp - PerkinElmer Inc - Promega Corp For more information visit http://www.researchandmarkets.com/research/267psb/medical Source: Plunkett Research Ltd
CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), ALR: 43.40 (-0.40), PKI: 46.30 (-0.10), HOLX: 30.46 (+0.21)
Alere (ALR) Disappoints; Misses on Earnings, Revenues in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:44AM CST
Alere Inc. (ALR) reported disappointing fourth-quarter 2014 results with both its top and bottom line missing the Zacks Consensus Estimate.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ALR: 43.40 (-0.40), SURG: 4.44 (-0.02)
Alere's (ALR) CEO Namal Nawana on Q4 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:07PM CST
ALR: 43.40 (-0.40)
Alere misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:02AM CST
ALR: 43.40 (-0.40)
Alere Inc. Announces Fourth Quarter 2014 Results
PR Newswire - Tue Feb 10, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, announced its financial results for the quarter ended December 31, 2014.
ALR: 43.40 (-0.40)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:30PM CST
WYN: 90.57 (+0.93), TLM: 7.63 (-0.03), CYNO: 31.37 (+0.80), PCG: 54.06 (-1.14), KKR: 24.42 (+0.06), GWR: 94.92 (-0.19), CDW: 37.03 (+0.63), ALLT: 9.15 (+0.02), HOT: 78.55 (+0.67), SAVE: 79.32 (-0.80), NSP: 48.91 (+1.20), MWW: 6.00 (+0.11), ACM: 27.79 (+0.82), DF: 16.19 (-0.11), REGN: 402.40 (+0.66), KO: 41.99 (-0.18), MLM: 145.23 (+3.15), RAI: 71.86 (-1.23), HCP: 42.87 (+0.20), SEE: 46.05 (-0.16), ENTG: 13.50 (-0.15), TAP: 72.82 (-0.96), ALR: 43.40 (-0.40), HNT: 55.97 (-0.43), OMC: 77.56 (+1.09), IMN: 3.93 (+0.13), SALE: 16.41 (+0.13), NILE: 29.02 (+0.07), CVS: 102.63 (-0.37), SFUN: 6.74 (-0.01)
Will Alere (ALR) Surprise Earnings Estimates This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 9:04AM CST
Alere Inc. (ALR) is set to report fourth-quarter 2014 results on Feb 10.
ACT: 285.37 (+3.71), ALNY: 95.54 (+1.67), UNH: 109.44 (-0.40), ALR: 43.40 (-0.40)
Alere Schedules Fourth Quarter 2014 Earnings Conference Call
PR Newswire - Tue Feb 03, 4:55PM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that it will release its financial results for the fourth quarter, ended December 31, 2014. The Company will host a conference call beginning at 8:30 a.m. ET on Tuesday, February 10, 2015, to discuss these results and provide business updates.
ALR: 43.40 (-0.40)
Chembio Acquires Rights to SURE CHECK(R) HIV 1/2 Assay Effective June 1, 2016
GlobeNewswire - Thu Jan 22, 9:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has entered into an agreement with StatSure Diagnostic Systems, Inc. (SDS) to acquire SDS' interest in the SURE CHECK HIV 1/2 Assay, effective June 1, 2016.
ALR: 43.40 (-0.40), CEMI: 3.96 (-0.04)
Chembio to own full rights to HIV 1/2 test by mid-2016
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:59AM CST
ALR: 43.40 (-0.40), CEMI: 3.96 (-0.04)
Health Care Supplies Stocks Technical Review - Cerus, Unilife, DENTSPLY Intl., Alere, and Align Technology
PR Newswire - Thu Jan 22, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Cerus Corporation (NASDAQ: CERS), Unilife Corporation (NASDAQ: UNIS), DENTSPLY International Inc. (NASDAQ: XRAY), Alere Inc. (NYSE: ALR), and Align Technology Inc. (NASDAQ: ALGN). Free research report on Cerus can be accessed at http://get.Investor-Edge.com/pdf/?c=Cerus&...amp;s=CERS. On Wednesday, January 21, 2015, the NASDAQ Composite ended at 4,667.42, up 0.27%, the Dow Jones Industrial Average advanced 0.22%, to finish the day at 17,554.28, and the S&P 500 closed at 2,032.12, up 0.47%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.90, up 0.11%, with the index also advancing 10.82% in the previous three months. Register for your complimentary reports at the links given below.
CERS: 5.53 (+0.08), ALGN: 56.90 (-0.34), UNIS: 4.32 (+0.06), ALR: 43.40 (-0.40), XRAY: 52.74 (+0.32)
Global Breath Analyzers Market 2014-2019 - Technology, by Application, by End User Analysis of the $1.53 Billion Industry
M2 - Mon Jan 19, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/9nfpk8/breath_analyzers) has announced the addition of the "Breath Analyzers Market by Technology, by Application, by End User - Analysis & Global Forecast to 2019" report to their offering. This market is expected to reach $1.53 billion in 2019 from $479.3 million in 2014 at a CAGR of 26.3% The breath analyzers market is categorized into four broad segments, namely, technology, applications, end users, and regions. The market, by technology, comprises fuel cell technology, semiconductor oxide sensor technology, and others. In 2014, the fuel cell technology segment accounted for the major share of the global market, by technology. Alcohol detection accounted for the largest share of the global market by application. Increasing alcohol and drug abuse, stringent government laws and regulations, an increase in the number of approvals from regulatory bodies, growing prominence of smartphone-based breath analyzers, and innovative product offerings (especially for medical applications) have stimulated the adoption of breath analyzers in the industry. However, in spite of numerous benefits, certain challenges such as inaccuracy and hygiene concerns are restraining the growth of this market. On the basis of end users, the breath analyzers market is segmented by law enforcement agencies, enterprises and individuals. Law enforcement agencies accounted for the largest share of the global market. Based on region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Africa, and Latin America) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Dynamics 6 Industry Trends 7 Breath Analyzers Market, By Technology 8 Breath Analyzers Market, By Application 9 Breath Analyzers Market, By End User 10 Breath Analyzers Market, By Geography 11 Competitive Landscape 12 Company Profiles - AK GlobalTech Corporation - Akers Biosciences, Inc. - Alcohol Countermeasure Systems Corporation - Alere, Inc. - BACtrack, Inc. - Dr?gerwerk AG & Co. KGaA - EnviteC-Wismar GmbH (A Honeywell Company) - Intoximeters, Inc. - Lifeloc Technologies - Mpd, Inc. - Quest Products, Inc. For more information visit http://www.researchandmarkets.com/research/9n..._analyzers
ALR: 43.40 (-0.40)
Global Infectious Disease Diagnostics Market 2014-2019 - Product, Application, Technology & End User Analysis of the $18 Billion Industry
M2 - Mon Jan 19, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/8vljzx/infectious) has announced the addition of the "Infectious Disease Diagnostics Market by Product, Application, Technology, End User - Global Forecast to 2019" report to their offering. The infectious disease diagnostics market is expected to grow at CAGR of 7.9% to reach $18.15 billion by 2019 from $12.42 billion in 2014 Increasing Prevalence of Deadly Infectious Disease and Need For Highly Specific and Sensitive Technologies for Rapid Diagnosis to Drive Growth of the IDD Market The immunodiagnostics and polymerase chain reaction technology segments accounted for the lion's share of the global IDD market by technology, owing to growing need for advanced technologies for rapid diagnosis of infectious diseases. On the basis of application, the IDD market is categorized into the Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), human papillomavirus (HPV), methicillin-resistant Staphylococcus aureus (MRSA), and others (Influenza, Ebola, Typhoid, Malaria, and Dengue, among others). Hospital-acquired MRSA infections, human papillomavirus, and AIDS are expected to be new revenue pockets in the applications market. The rising prevalence of these diseases globally is the major factor driving the growth of the aforementioned markets. On the basis of product, the IDD market is segmented into instruments, consumables (reagents and assays), and software & services. Among products, consumables are estimated to be the fastest-growing market owing to its growing adoption in emerging infectious disease diagnostics worldwide. On the basis of end user, the market is segmented into hospital laboratories, reference labs, physician's office labs, academics, and others (blood banks, local public health laboratories, home health agencies, nursing homes, point of care, self-testing). Hospital laboratories are expected to be the fastest-growing market in the forecast period. Owing to the complexity and highly specialized nature of diagnostic tests for infectious diseases, hospital laboratories are expected to grow at the fastest rate in the forecast period, from 2014 to 2019. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Infectious Disease Diagnostics Market, By Product 8 Infectious Disease Diagnostics Market, By Application 9 Infectious Disease Diagnostics Market, By Technique 10 Infectious Disease Diagnostics Market, By End User 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - Abbott Laboratories - Alere, Inc. - Becton, Dickinson & Co. - Bio-Rad Laboratories - Biom?rieux - Danaher Corporation - Johnson and Johnson - Roche Diagnostics - Siemens Healthcare - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8vljzx/infectious
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), BDX: 143.71 (+0.72), DHR: 86.81 (+0.21), ALR: 43.40 (-0.40)
Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019
M2 - Fri Jan 16, 8:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/cl7fxt/microbiology) has announced the addition of the "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application & by Industry - Global Forecast to 2019" report to their offering. The global clinical microbiology market is expected to reach $12,411.36 million in 2019 at a CAGR of 13.03% between 2014 and 2019. Clinical microbiology consists of a wide array of techniques for the detection of infectious diseases. The respiratory diseases segment accounted for the largest application segment of the clinical microbiology market in 2014. According to the WHO, in 2012, there were about 450,000 new cases of multidrug-resistant tuberculosis (MDR-TB), and extensively drug-resistant tuberculosis (XDR-TB) was identified in 92 countries. Furthermore, the outbreak of new diseases such as Ebola is expected to increase the disease burden and the demand for clinical microbiology products. The microbiology market is segmented on the basis of applications into clinical, energy, environment, food, manufacturing, and pharmaceuticals. The food application segment is expected to grow at the highest CAGR between 2014 and 2019 however, the pharmaceuticals application segment accounted for the largest share of the microbiology market in 2014. On the basis of products, the clinical microbiology market is segmented into consumables and instruments. The clinical microbiology consumables market is further bifurcated into kits and reagents, whereas the instruments market is sub segmented into automated microbiology instruments, laboratory instruments, and microbiology analyzers. The microbiology analyzers are further categorized into mass spectrometers, microscopes, and molecular diagnostics instruments. The laboratory instruments are further categorized into anaerobic gas systems, automated gram strainers, automated petri dish fillers, autoclave sterilizers, bacterial colony counters, incubators, microbial air samplers, and other laboratory instruments. Clinical microbiology finds applications in a large number of disease diagnosis. The clinical microbiology market on the basis of applications are segmented into bloodstream infections, gastrointestinal diseases, periodontal diseases, respiratory diseases, sexually transmitted diseases, urinary tract infections, and other diseases. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Microbiology Market, By Applications 8 Clinical Microbiology Market, By Product 9 Clinical Microbiology Market, By Applications 10 Clinical Microbiology Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - Biom?rieux SA - Bruker Corporation - Cepheid - Danaher Corporation - F. Hoffmann-LA Roche Ltd. - Hologic, Inc. - Siemens AG For more information visit http://www.researchandmarkets.com/research/cl...crobiology
ABT: 46.09 (+0.87), CPHD: 59.62 (+0.72), DHR: 86.81 (+0.21), ALR: 43.40 (-0.40), HOLX: 30.46 (+0.21)
Alere (ALR) Closes Alere Health Sale to Optum for $600M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 12:30PM CST
The sale of Alere Health is part of Alere Inc.'s (ALR) key strategic objective to divest its non-core operations to focus on core areas like rapid diagnostics and improve balance sheet strength.
ABT: 46.09 (+0.87), BDX: 143.71 (+0.72), UNH: 109.44 (-0.40), ALR: 43.40 (-0.40)
Alere Set to Possibly Pullback After Yesterday's Rally of 1.31%
Comtex SmarTrend(R) - Fri Jan 09, 4:34PM CST
Alere (AMEX:ALR) traded in a range yesterday that spanned from a low of $39.58 to a high of $40.68. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALR: 43.40 (-0.40)
Alere Inc. Completes Divestiture of Alere Health
PR Newswire - Fri Jan 09, 3:10PM CST
Alere Inc. (NYSE: ALR) today announced the completion of the previously announced sale of Alere Health and its subsidiaries, which provide leading condition management, case management, wellbeing, wellness and women's and children's health services to regional and local health plans, Fortune 500 employers and state governments, to Optum for $600 million in cash.
ALR: 43.40 (-0.40)
Alere's (ALR) Influenza Test Gets CLIA Waiver from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 11:10AM CST
With the CLIA waiver from the FDA, Alere Inc.'s (ALR) i Influenza A & B test can now be used across a wide variety of clinical settings.
ABT: 46.09 (+0.87), JNJ: 99.62 (+1.18), BDX: 143.71 (+0.72), ALR: 43.40 (-0.40)
Alere Receives FDA CLIA Waiver for Alere(TM) i Influenza A & B Test
PR Newswire - Wed Jan 07, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere(TM) i Influenza A & B test, the only molecular test to detect and differentiate influenza A and B virus in under 15 minutes. Alere i Influenza A & B is the first-ever molecular test to receive a CLIA (Clinical Laboratory Improvement Amendments) waiver, which allows for broad use by healthcare providers, ranging from hospitals and physician offices to clinics and other healthcare settings.
ALR: 43.40 (-0.40)
Alere to Present at 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 05, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that CEO and President Namal Nawana will present at the 33rd annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 7:30 a.m. PST. The conference will be held at the Westin St. Francis in San Francisco, Calif.
JPM: 59.67 (+0.10), ALR: 43.40 (-0.40)
Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021
M2 - Mon Dec 15, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/267psb/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.) to reach $19.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alere Inc - Bio Rad Laboratories Inc - Cepheid - Hologic GenProbe Inc - Hologic Inc - Illumina Inc - Immucor Inc - Life Technologies Corp - PerkinElmer Inc - Promega Corp For more information visit http://www.researchandmarkets.com/research/267psb/medical Source: Plunkett Research Ltd
CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), ALR: 43.40 (-0.40), PKI: 46.30 (-0.10), HOLX: 30.46 (+0.21)
